Vitiligo
Conditions
Interventions
Experimental group:Baritinib was taken orally 4mg once a day, combined with NB-UVB twice a week for 6 months
Sponsors
Dermatology Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Diagnostic criteria of progressive nonsegmental vitiligo,VIDA score >= 1; 2) Patients with moderate to severe nonsegmental vitiligo involving the face and neck were selected, with leukoplakia area >= 5%; 3) Patients with poor efficacy of routine treatments such as oral glucocorticoids or phototherapy given systematically; 4) Informed and agreed to participate in this study; 5) Patients aged between 18 and 65 years old.
Exclusion criteria
Exclusion criteria: 1) Segmental vitiligo and non-segmental vitiligo with an area 15 x 10^9/L, lymphocytes 1.5 ULN; Serum creatinine, BUN>1.5 ULN; Triglycerides or total cholesterol>1.5 ULN; Women of childbearing age have a positive pregnancy test; 8) A history of human immunodeficiency virus (HIV) or HIV seropositivity during screening, or infection with hepatitis B or C virus. There is evidence that Mycobacterium tuberculosis (TB) is active, latent or inadequately treated; 9) Those who have participated in other clinical trials in the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| vitligo area; | — |
Countries
China
Contacts
Public ContactGuangpu Luo
Dermatology Hospital, Southern Medical University
Outcome results
None listed